Our development pipeline includes targeted programs designed to combat serious multidrug-resistant infections caused by both Gram-negative bacteria, such as Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa, as well as Gram-positive pathogens. We are dedicated to addressing the growing threat of antimicrobial resistance across a broad spectrum of harmful bacteria.